Q3 EPS Estimates for Scholar Rock Lowered by HC Wainwright

Scholar Rock Holding Corporation (NASDAQ:SRRK) – Analysts at HC Wainwright cut their Q3 2026 EPS estimates for Scholar Rock in a note issued to investors on Friday, August 7th. HC Wainwright analyst A. Maldonado now anticipates that the company will earn ($0.84) per share for the quarter, down from their prior estimate of ($0.82). HC Wainwright currently has a “Buy” rating and a $65.00 target price on the stock. The consensus estimate for Scholar Rock’s current full-year earnings is ($3.25) per share. HC Wainwright also issued estimates for Scholar Rock’s Q4 2026 earnings at ($0.78) EPS, FY2026 earnings at ($3.29) EPS, FY2027 earnings at ($2.45) EPS, FY2028 earnings at ($0.86) EPS, FY2029 earnings at $0.35 EPS and FY2030 earnings at $1.40 EPS.

Scholar Rock (NASDAQ:SRRK) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.84) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.84). During the same period in the previous year, the company posted ($0.98) EPS.

Other analysts have also recently issued research reports about the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Scholar Rock in a report on Friday, July 17th. Wedbush restated an “outperform” rating and issued a $58.00 price objective on shares of Scholar Rock in a report on Monday. BMO Capital Markets reaffirmed an “outperform” rating and issued a $76.00 target price on shares of Scholar Rock in a research report on Friday. Citigroup lifted their target price on shares of Scholar Rock from $58.00 to $60.00 and gave the company a “buy” rating in a research note on Friday. Finally, Canaccord Genuity Group started coverage on shares of Scholar Rock in a research report on Monday, April 20th. They set a “buy” rating and a $62.00 price target on the stock. Four analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $56.79.

Scholar Rock Price Performance

SRRK opened at $51.89 on Tuesday. The company has a debt-to-equity ratio of 0.71, a quick ratio of 8.64 and a current ratio of 8.64. Scholar Rock has a 52-week low of $27.07 and a 52-week high of $58.49. The stock has a market capitalization of $6.32 billion, a PE ratio of -15.04 and a beta of 0.69. The stock’s 50 day moving average price is $50.15 and its 200-day moving average price is $47.92.

Institutional Trading of Scholar Rock

Institutional investors have recently bought and sold shares of the company. GAMMA Investing LLC raised its holdings in Scholar Rock by 20.8% in the second quarter. GAMMA Investing LLC now owns 1,406 shares of the company’s stock worth $77,000 after buying an additional 242 shares during the last quarter. Values First Advisors Inc. grew its holdings in shares of Scholar Rock by 1.5% during the first quarter. Values First Advisors Inc. now owns 18,850 shares of the company’s stock valued at $927,000 after buying an additional 286 shares during the last quarter. IFP Advisors Inc grew its holdings in shares of Scholar Rock by 294.1% during the fourth quarter. IFP Advisors Inc now owns 603 shares of the company’s stock valued at $27,000 after buying an additional 450 shares during the last quarter. EverSource Wealth Advisors LLC increased its position in shares of Scholar Rock by 151.3% during the fourth quarter. EverSource Wealth Advisors LLC now owns 872 shares of the company’s stock valued at $38,000 after acquiring an additional 525 shares in the last quarter. Finally, California State Teachers Retirement System increased its position in shares of Scholar Rock by 0.9% during the second quarter. California State Teachers Retirement System now owns 62,372 shares of the company’s stock valued at $2,209,000 after acquiring an additional 577 shares in the last quarter. 91.08% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Scholar Rock

In other Scholar Rock news, Director Kristina Burow sold 3,053 shares of the business’s stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $53.74, for a total value of $164,068.22. Following the sale, the director directly owned 114,657 shares of the company’s stock, valued at approximately $6,161,667.18. The trade was a 2.59% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Joshua Reed sold 3,053 shares of the business’s stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $53.74, for a total value of $164,068.22. Following the completion of the sale, the director directly owned 19,518 shares in the company, valued at $1,048,897.32. This trade represents a 13.53% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 17,149 shares of company stock valued at $923,108 in the last ninety days. Corporate insiders own 10.30% of the company’s stock.

Scholar Rock Company Profile

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).